Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML) Meeting Abstract

  


Authors: Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Douer, D.; Estey, E. H.; Kantarjian, H. M.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML)
Meeting Title: 55th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 122
Issue: 21
Meeting Dates: 2013 Dec 7-10
Meeting Location: New Orleans, LA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2013-11-15
Language: English
ACCESSION: WOS:000331385003100
PROVIDER: wos
DOI: 10.1182/blood.V122.21.1460.1460
Notes: Meeting Abstract: 1460 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jae Hong Park
    356 Park
  2. David Scheinberg
    499 Scheinberg
  3. Dan Douer
    87 Douer
Related MSK Work